在中年成人中,胎儿酒精谱系障碍的皮质下体积
Amanda Bischoff-Grethe1, Susan A Stoner2, Edward P Riley3
1Department of Psychiatry, University of California, San Diego, La Jolla, CA, 92093, USA.
Brain communications
|September 4, 2024
概括
患有胎儿酒精谱系障碍 (FASD) 的成年人表现出持续的大脑体积减少,特别是在皮下结构中. 患有FASD的女性可能会经历加速的体退化,影响衰老的认知.
科学领域:
- 神经科学是一个神经科学.
- 发展心理学 发展心理学
- 放射学 放射学是一门学科.
背景情况:
- 产前酒精暴露 (PAE) 与年轻人的大脑体积减少有关,影响大脑体,小脑和皮下结构.
- 目前尚不清楚这些体积缺陷是否会持续到中年成人,或者PAE患者是否会经历与年龄相关的加速体积下降.
研究的目的:
- 为了研究与健康对照组相比,30-65岁的胎儿酒精谱系障碍 (FASD) 的成年人中持续存在的大脑体积差异.
- 检查衰老和性别对这些体积差异的影响.
主要方法:
- 包括T1和T2加权图像在内的结构性MRI (3T) 被从48名患有FASD的成年人和28名健康对照 (年龄在30-65岁) 中获得.
- 使用FreeSurfer进行了尾骨,骨,骨,小脑和大脑体的体积测量.
- 统计模型分析了群体,年龄和性别的主要影响及其相互作用,考虑了原始和内正常化的体积.
主要成果:
- 与对照组相比,患有FASD的参与者在所有测量的大脑区域中表现出明显较小的体积,无论正常化 (P <0.001原始;P <0.046正常化).
- 没有观察到群体和年龄之间的显著相互作用.
- 与患有FASD的健康女性和男性相比,患有FASD的女性显示身体体体积明显较小 (P < 0.001).
结论:
- 患有FASD的成年人表现出皮下和体体积的持续减少,与在年轻人群中观察到的效应一致.
- 在患有FASD的女性中,体体积的减少可能表明加速退化,可能会在衰老过程中影响认知功能.
更多相关视频
相关概念视频
Mass Spectrometry: Alcohol Fragmentation
Alcohols (R-OH) ionize to lose one non-bonded electron from the oxygen atom, forming molecular ions. Due to their tendency to fragment rapidly, the intensity of the molecular ion peak in the mass spectrum is weak or sometimes absent. The fragmentation patterns for alcohols occur in two ways, i.e. ⍺-cleavage and dehydration. During ⍺-cleavage, the bond at the ⍺-position adjacent to the hydroxyl group cleaves to give a resonance-stabilized cation and a radical. However, intramolecular dehydration...
Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...


